Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Division of Hematology-Oncology, Department of Medicine, University of California at San Francisco, San Francisco, California 94143, USA.
Patients with chronic phase chronic myeloid leukemia who respond to imatinib have a rapid initial decrease in BCR-ABL transcript levels (α), followed by a slow decline (β). The rate of β decrease is consistent with declining leukemic stem cells and may predict which patients may safely discontinue therapy.
©2011 AACR
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on